Optimization of the radiosynthesis of the PSMA-targeting drugs [¹⁷⁷Lu]Lu-P17-087 and [¹⁷⁷Lu]Lu-P17-088 on the MiniLu™ automated module.

ABSTRACT:

Background

There is a renewed interest in radioligand therapy for cancer treatment since the approval of Lu-177 vipivotide tetraxetan (PSMA-617) by regulators in Europe and the United States for metastatic castrate resistant prostate cancer (mCRPC) patients. Recent expansion of indications for vipivotide tetraxetan in mCRPC by the FDA promises to increase demand for this class of radioligand therapy. The development of new targeted radioligands for mCRPC that improve binding specificity and increase radiation dose delivered to tumors is an active research space. [¹⁷⁷Lu]Lu-P17-087 and [¹⁷⁷Lu]Lu-P17-088 are new prostate specific membrane antigen (PSMA) targeted drugs under clinical investigation in China. Heretofore the preparation of these investigational drugs

SUBMITTER: Alexoff D 

PROVIDER: S-EPMC12623512 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature